These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 19576176)

  • 1. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.
    Covy JP; Giasson BI
    Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.
    Carballo-Carbajal I; Weber-Endress S; Rovelli G; Chan D; Wolozin B; Klein CL; Patenge N; Gasser T; Kahle PJ
    Cell Signal; 2010 May; 22(5):821-7. PubMed ID: 20074637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease.
    Qing H; Zhang Y; Deng Y; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1229-34. PubMed ID: 19878656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pathological characterization of Lrrk2.
    Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
    Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants.
    Xiromerisiou G; Hadjigeorgiou GM; Gourbali V; Johnson J; Papakonstantinou I; Papadimitriou A; Singleton AB
    Eur J Neurol; 2007 Jan; 14(1):7-11. PubMed ID: 17222106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
    Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
    Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients.
    Tan YY; Wu L; Zhao ZB; Wang Y; Xiao Q; Liu J; Wang G; Ma JF; Chen SD
    Parkinsonism Relat Disord; 2014 Mar; 20(3):308-13. PubMed ID: 24398085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
    Gomez A; Ferrer I
    Acta Neuropathol; 2010 Aug; 120(2):155-67. PubMed ID: 20232069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
    Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
    Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
    Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
    Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?
    Outeiro TF; Harvey K; Dominguez-Meijide A; Gerhardt E
    Biochem Soc Trans; 2019 Jun; 47(3):827-838. PubMed ID: 31085616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autosomal dominant Parkinson's disease and the route to new therapies.
    Morris HR
    Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CADPS2 gene expression is oppositely regulated by LRRK2 and alpha-synuclein.
    Obergasteiger J; Überbacher C; Pramstaller PP; Hicks AA; Corti C; Volta M
    Biochem Biophys Res Commun; 2017 Aug; 490(3):876-881. PubMed ID: 28647363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.